Annovis Bio Inc ANVS 深 沪
等待开盘 02-19 09:30:00 美东时间
2.43
+0.050
+2.10%
华盛通- 最 高2.51
- 今 开2.39
- 成交量 20.93万股
- 最 低 2.35
- 昨 收 2.38
- 总市值 6440.20万
- 52周最高 5.50
- 市盈率 静 --
- 换手率 0.79%
- 52周最低 1.11
- 委 比 88.68%
- 总股本 2650.29万
- 历史最高 132.00
- 量 比 0.66
- 振 幅 6.72%
- 历史最低 1.11
- 每 手 1
- 风险率 0.79%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多BRIEF-Annovis Announces Open-Label Extension Study For Parkinson's Disease Patients
Dec 18 (Reuters) - Annovis Bio Inc ANVS.N: ANNOVIS ANNOUNCES OPEN-LABEL EXTENSION STUDY FOR PARKINSON'S DISEASE PATIENTS ANNOVIS BIO INC - TO BEGIN OPEN-LABEL EXTENSION STUDY IN JANUARY 2026 Source te...
2025-12-19 07:25
Annovis Bio Advances Long-Term Buntanetap Safety Study in Parkinson’s Disease
Annovis Bio Inc ($ANVS) announced an update on their ongoing clinical study. St...
2025-12-19 00:31
Annovis to Host Corporate Update Webinar on January 28, 2026
Annovis Bio, Inc. will host a corporate update webinar on January 28, 2026, featuring Maria Maccecchini, Ph.D., President and CEO, discussing the Company’s recent progress, clinical programs, and strategic directions. The webinar is open to shareholders, patients, and interested parties, with a live Q&A session. Registration is available via the provided link, and pre-submitted questions can be sent to ir@annovisbio.com.
2025-12-16 13:00
Annovis Bio Director Michael B. Hoffman Reports Acquisition of Common Shares
Michael B. Hoffman, Director of Annovis Bio Inc., reported the acquisition of common shares of the company. The full filing can be accessed through the link below. Disclaimer: This news brief was crea...
2025-12-09 09:05
Annovis To Present at the 2025 Annual Meeting of the Parkinson Study Group
<p>Annovis Bio, a company developing treatments for neurodegenerative diseases, announced its participation in the 2025 Parkinson Study Group Annual Meeting in San Diego, where it will present data on its drug, buntanetap. The presentation will highlight recent Phase 3 findings showing that buntanetap counteracts cognitive decline and reduces tau biomarkers in Parkinson’s disease patients with amyloid co-pathology. Additionally, cross-study compa...
2025-12-03 13:00
美股牛股 | 绩优股集体大爆发！柯尔百货暴涨超42%，连续两季度上调业绩指引；Symbotic大涨近40%
绩优股集体大爆发！柯尔百货暴涨超42%，连续两季度上调业绩指引；Symbotic大涨近40%，年内涨幅达226%>>
2025-11-26 16:15
Annovis Announces Two Presentations at the CTAD 2025 Conference
Annovis Bio, Inc. will present two studies at the 18th Clinical Trials on Alzheimer's Disease (CTAD) conference in San Diego. The presentations will focus on buntanetap, a potential disease-modifying therapy for Alzheimer's and Parkinson's diseases. Presentation P073 by Cheng Fang, Ph.D., will discuss amyloid co-pathology and cognitive decline in Parkinson's dementia patients treated with buntanetap, while Presentation P007 by Maria Maccecchini, ...
2025-11-24 13:00
BUZZ-U.S. STOCKS ON THE MOVE-Sunoco, Albemarle, GE Healthcare Technologies
Eikon search string for individual stock moves: STXBZ The Day Ahead newsletter: https://refini.tv/3LI4BU7 The Morning News Call newsletter: https://refini.tv/3dKUyB8 Wall Street's main indexes struggl...
2025-11-17 23:50
Annovis Bio Data From Phase 3 Trila In Early Parkinson's Demonstrates Buntanetap Halted Cognitive Decline Across Overall Patient Count
Annovis Bio, Inc. (NYSE: ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's
2025-11-17 21:01
Annovis Bio GAAP EPS of -$0.37
Annovis Bio press release (ANVS): Q3 GAAP EPS of -$0.37. Annovis’ cash and cash equivalents totaled $15.3 million as of September 30, 2025, compared to $10.6 million as of December 31, 2024. More on A...
2025-11-12 22:18
